Table 7 Consent processes and understanding of the trial (Household survey)
| Â | Site A | Site B | Site C | Total |
|---|---|---|---|---|
|  | n = 67 (%) | n = 33 (%) | n = 100 (%) | n = 200 (%) |
Main purpose of the trial | Â | Â | Â | Â |
Provide treatment/help to participating children | 32 (47.8) | 18 (54.5) | 71 (71.0) | 121 (60.5) |
Learn about potential for preventing malaria | 27 (40.3) | 12 (36.4) | 23 (23.0) | 62 (31.0) |
DK | 3 (4.5) | 1 (3.0) | 3 (3.0) | 7 (3.5) |
Other activities | 2 (3.0) | 0 | 2 (2.0) | 4 (2.0) |
Missing/data not clear to code | 3(4.5) | 2 (6.1) | 1 (1.0) | 6 (3.0) |
Did all children in the trial get a malaria vaccine? | Â | Â | Â | Â |
Yes | 38 (56.7) | 19 (57.6) | 63 (63.0) | 120 (60.0) |
No | 12 (17.9) | 6 (18.2) | 11 (11.0) | 29 (14.5) |
DK | 17 (25.4) | 8 (24.2) | 24 (24.0) | 49 (24.5) |
Missing data | 0 | 0 | 2 (2.0) | 2 (1.0) |
Do you think children who got trial vaccines are still able to get malaria? | Â | Â | Â | Â |
Yes | 10 (14.9) | 5 (15.2) | 15 (15.0) | 30 (15.0) |
No | 32 (47.8) | 17 (51.5) | 56 (56.0) | 105 (52.5) |
DK | 25 (37.3) | 11 (33.3) | 28 (28.0) | 64 (32.0) |
Missing data | 0 (0) | 0 | 1 (1.0) | 1 (0.5) |
Would consider participating in future similar trial? | Â | Â | Â | Â |
Agree | 45 (67.2) | 20 (60.6) | 80 (80.0) | 145 (72.5) |
Not agree | 2 (3.0) | 0 | 0 | 2 (1.0) |
Indifferent/DKa | 20 (29.9) | 13 (39.4) | 20 (20.0) | 53 (26.5) |
Content with decision to enrol your child in the trial? | Â | Â | Â | Â |
Yes | 61 (91.0) | 31 (93.9) | 94 (94.0) | 186 (93.0) |
No | 4 (6.0) | 0 | 2 (2.0) | 6 (3.0) |
Indifferent | 2 (3.0) | 2 (6.1) | 4 (4.0) | 8 (4.0) |
Most important reasons for enrolling in trial (top five) | Â | Â | Â | Â |
Access to free treatment | 18 (26.9) | 10 (30.3) | 35 (35.0) | 63 (31.5) |
Access to better and quality services | 9 (13.4) | 6 (18.2) | 25 (25.0) | 40 (20.0) |
Vaccine beneficial | 12 (17.9) | 5 (15.2) | 13 (13.0) | 30 (15.0) |
Detailed explanation of the study | 5 (7.5) | 3 (9.1) | 7 (7.0) | 15 (7.5) |
Previous experience/interaction with KEMRI | 3 (4.5) | 4 (12.1) | 6 (6.0) | 13 (6.5) |